A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

NCT05585320 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

209

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Pancreatic Adenocarcinoma
Malignant Melanoma (Cutaneous)
Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: IMM-1-104 Monotherapy (Treatment Group A)
DRUG: IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)
DRUG: IMM-1-104 + modified FOLFIRINOX (Treatment Group C)
DRUG: IMM-1-104 + dabrafenib (Treatment Group D)
DRUG: IMM-1-104 + pembrolizumab (Treatment Group E)

Sponsor

Immuneering Corporation